Memphasys (ASX:MEM) confirmed the RoXsta Mega Cell High-Throughput Assay device was capable of simultaneously processing 96 samples in less than an hour during recent trials, according to a Thursday filing with the Australian bourse.
The diagnostic device has been developed for rapid and high-capacity testing of reactive oxygen species levels in biological fluids, the filing said.
The device has been utilized in various studies, including assessing oxidative stress in cattle and assessing antioxidant levels in professional footballers, per the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。